

Unaudited Financial Results for the Quarter ended on 30th Sept, 2008 **Rs.in Lacs** Particulars Six Months Sr Quarter Ouarter Six Months Year No. ended on ended on ended on ended on ended on 3/31/2008 9/30/2008 9/30/2007 9/30/2008 9/30/2007 Unaudited Unaudited Unaudited Unaudited Audited 1733.20 3263.37 602.17 1502.40 (a) Net Sales/ Income from Operations 875.03 (b) Other Operation Income Expenses (a) (Increase)/decrease in Stock in trade -209.76 -44.83 -210.70 -31.67 -198.97 154.62 628.17 (b) Consumption of Raw material 175.88 300.16 285.67 (c) Trading Purchase 0.15 19.06 10.46 38.74 42.32 344.98 (d) Manufacturing Expenses 130.76 88.04 239.21 169.55 85.48 65.24 164.45 121.88 299.40 (e) Staff Cost (f) Depreciation 95.56 92.27 186.77 173.80 368.46 113.88 100.12 220.23 450.09 (g) Other expenditure 209.48 (h) Total 370.69 495.78 910.58 967.45 1934.45 Profit from Operations before Other 231.48 379.25 591.82 765.75 1328.92 Income, Interest & Exceptional items(1-2) 4 Other Income 0.01 3.94 0.30 14.55 27.51 Profit before Interest & Exceptional Items 231.49 383.19 780.30 1356.43 5 592.12 6 Interest 73.66 70.40 141.27 141.36 265.49 Profit after Interest but before exceptioanl items (5-6) 312.79 450.85 638.94 157.83 1090.94 7 8 Exceptional Item 0 0 0 0 0 Profit(+)/Loss(-) from Ordinary Actvities before tax 9 312.79 450.85 157.83 638,94 1090.94 (7+8)10 Tax expenses 54.00 108.00 155.10 210.80 386.86 Net Profit(+)/Loss(-) from Ordinary Activities after tax 11 103.83 204.79 295.75 428.14 704.08 12 Extraordinary Item (net of tax expense) 0 0 0 0 13 Net Profit(+)/Loss(-) for the period 103.83 204.79 295.75 428.14 704.08 Paid-up equity share capital (Face value of Rs. 10/-519.12 519.12 519.12 519.12 519.12 14 Reserves & Surplus excluding revaluation Reserves as 15 16 EPS (Rs.) (not annualised) (a)Basic & Diluted before Extraordinary item 2.00 3.94 5.70 8.25 13.56 (b)Basic & Diluted after Extraordinary item 2.00 3.94 5.70 8.25 13.56 17 **Public Shareholding** 2952124 2952124

Note:

Place:

Date:

- Number of Share

Ahmedabad 24.10.2008

- 56.87 56.87 56.87 56.87 56.87 - % of Shareholding 1. The Board of Directors have approved the aforesaid working result at their meeting held on 24th October, 2008 after reviewed by the audit Committee of
- 2. The Limited Review Report for the quarter as required under clause 41 of the listing agreement with Stock Exchange has been carried out by the Statutory
- 3. The drop in turnover was indirectly attributed to the temporary steep rise in commodity prices (maize and soya) which compelled the poultry companies to reduce their production, thereby reducing their requirement for poultry vaccines.
- 4. Segment wise reporting as defined in Accounting Standard (AS-17) is not applicable, since the entire operation of the Company related to only one segment i.e. "Poultry Vaccines".
- 5. No investor complaints were pending at the beginning and at the and of the quarter. During the quarter, three complainmts were received and resolved.
- 6. Provision for taxation includes Current Tax, FBT and Deferred Tax Liability for the quarter as per Accounting Standard (AS-22)

By order of the Board

2952124

2952124

CEO & Managing Director

Formerly Hester Pharmaceuticals Limited

Hester Biosciences Limited

2952124